The Medtronic merger with Covidien could offer a particular threat to C.R. Bard's vascular business--its largest segment and one of its fastest growing. The company was clear that it's actively in the market for its own strategic acquisitions; it hasn't disclosed a sizeable deal in almost a year.
Covidien is celebrating third quarter earnings buoyed by strong sales, with its surgical solutions unit and progress in emerging markets generating an sizeable increase in cash flow.
AbbVie may have just struck a deal with Shire in order to diversify beyond its top drug, Humira. But that doesn't mean the drug isn't steamrolling.
Varian Medical Systems closed out a winning streak, while AngioDynamics deepened its losses when each company reported earnings for the second quarter.
Eli Lilly's animal health business, Elanco, provides a bit of a bright spot in an otherwise weak earning report for its second quarter, with sales globally up more than 10%, while revenues across the entire company were up just 1%.
Bristol-Myers Squibb's melanoma drug Yervoy and clot-fighter Eliquis helped boost its earnings past analyst forecasts, with $333 million in profits on $3.9 billion in revenue.
Blame a strong Swiss franc on any falling sales and profits Roche put up in the first half of 2014, the company said Thursday. The Swiss pharma's cancer drugs certainly didn't cause the decline, with newcomers Perjeta and Kadcyla helping power the group with especially noteworthy revenue gains.
Intuitve Surgical had to defend its robotic surgery platform again, this time from a study which reports that insurance claims data shows that bladder cancer patients had a similar complication rate and length of hospital stay regardless of whether their bladder was removed robotically or in a more invasive open procedure.
Protecting patients from unnecessary exposure to radiation is the aim of start-up Augmenix. To advance its efforts and achieve profitability, the company has raised a $10.8 million Series D round. It also disclosed that an option, which Varian Medical Systems ($VAR) had gained to acquire the company under a 2011 financing, has expired.
Zimmer Holdings charted sizable sales gains for the second quarter with adjusted net earnings growing 4.6% from the prior year's period, but lowered its full-year estimates due to manufacturing expenses and costs associated with its pending Biomet merger.